title: [Therapy of virginal prostatic cancer with cyproterone acetate].
abstract: 52 patients with virginal carcinoma of the prostate were treated with 100 mg cyproterone acetate during an observation period of 12 to 68 months (average 38.2 months). In 7 patients (13.5%) the therapy had to be stopped because of gastrointestinal intolerability. Of 45 patients in whom a relevant clinical statement was possible 44.4% showed a progression of the disease after a period of 3 to 30 months (on average 10.8 months). 95% of these patients had carcinomas with a higher degree of malignity (GII or GIII). From this is concluded that the monotherapy of the medium- to undifferentiated carcinoma of the prostate with cyproterone acetate is to be refused in this dosage.
authors.forename: U
authors.initials: U
authors.lastname: Maier
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013739:Testosterone / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D013739:Testosterone; D017373:Cyproterone Acetate; D003534:Cyproterone
vernacular_title: Therapie des virginellen Prostatakarzinoms mit Cyproteronacetat.